Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration | BMJ Case Reports

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Global health

Authors

About

Help
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Findings that shed new light on the possible pathogenesis of a disease or an adverse effect

CASE REPORT

Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Klein K, Asaad S, Econs M, et al

Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration

Case Reports 2018;2018:bcr-2017-222851.